Sanofi Expands Patient App After 25,000 Users Deliver 4% Therapy Discontinuation Drop
BrightInsight’s Patient App, co-developed with Sanofi, has been adopted by over 25,000 patients and reduced discontinuation of a key biologic therapy by 4% in real-world data from 6,000 patients after one year. Based on strong user feedback, Sanofi is expanding the app partnership across key international markets and its specialty care portfolio to enhance patient adherence.
1. Sanofi Expands Digital Health Partnership Following Positive Adherence Data
Sanofi has announced an expansion of its collaboration with BrightInsight after real-world data demonstrated meaningful improvements in patient adherence and persistence for one of its key self-injected biologic therapies co-developed with Regeneron. Since its limited launch, the BrightInsight Patient App has been adopted by more than 25,000 patients. An analysis of data from over 6,000 users across multiple indications showed a 4% reduction in therapy discontinuation and measurable gains in adherence after one year, compared to a non-app cohort. These results exceed historical adherence rates of approximately 50% in self-injected therapies, according to World Health Organization studies, and address industry challenges where up to 63% of patients discontinue treatment within 12 months. Based on strong user feedback and these outcomes, Sanofi will roll out the Patient App across key international markets and extend its deployment across additional specialty care indications, leveraging the BrightInsight Platform’s global compliance and data-analytics capabilities.